Surveillance of patients with a history of cancer is a frequent practice in oncology. However, it is often aimed at the early diagnosis of relapse and tends to underestimate the evaluation and care of factors impairing quality of life (QoL). Among these, long-term toxicities of anticancer treatments are one of the major threats to a complete physical and psychosocial recovery. We aimed to review the relevant literature on long-term side-effects of treatment in gastrointestinal cancers.
INTRODUCTION
Gastrointestinal cancers encompass a large spectrum of diseases, and clinical presentation, treatment modalities and overall prognosis differ significantly among these. Although with variable proportions, long-term survival is becoming more common, given the progressive improvement of anticancer treatments. However, a significant part of survivors suffer from treatment-related side-effects: surgery, radiotherapy and chemotherapy can all induce late toxicities that need to be acknowledged and managed in order to restore a good quality of life (QoL). Survivorship care should be an important target of cancer surveillance, together with the early identification of relapse. Using available data, we will focus on the common late effects of cancer treatments that need to be recognized in the survivorship care of esophageal, gastric, liver, pancreatic and colorectal cancers.
ESOPHAGEAL CANCER
Approximately, 30% of patients with early stage cancer are long-term survivors, whereas the proportion lowers in the case of locally advanced disease [1] . Standard treatment of patients with tumors confined to the esophageal wall (T1ÀT3) is surgery. Radiotherapy can replace surgery in the case of medical reasons of inoperability. Chemo-radiotherapy is the standard treatment for patients with locoregionally advanced disease [2, 3] . Chemotherapy and chemo-radiotherapy can also be employed as induction treatment before loco-regional treatment. Randomized studies have suggested that the surgical and nonsurgical approaches have similar long-term results in terms of disease-free and overall survival [4] . Esophagectomy carries a high risk of short-term mortality or complications and of poor long-term QoL [5] . Both surgery and the related acute complications affect long-term QoL. Several studies have shown that QoL is impaired in a substantial proportion of patients [6] : it worsens immediately after surgery, although many patients are able to regain their preoperative state within 6-12 months. This, however, does not translate into a normal condition, because of the persistence of several symptoms [7] [8] [9] [10] [11] [12] . In a nationwide Swedish population prospective cohort study comparing 117 patients undergoing radical esophagectomy with healthy controls and followed-up to 10 years, QoL was significantly worse in the operated patients. General symptoms affecting QoL were pain, fatigue, appetite loss, diarrhea, dyspnea, constipation, nausea and vomiting. Reported esophageal-specific symptoms were dysphagia, eating difficulties, esophageal pain and reflux. In terms of trajectory, while in the majority of the sample QoL fully recovered between 6 months and 3 years after surgery, in a small proportion QoL did not improve or even worsened [13] . In another series investigating QoL 5 years after surgery, swallowing impairment and reflux were still a problem for most patients [14] . Surgical approach (transhiatal or transthoracic esophagectomy) and type of anastomosis (manual or mechanical) do not seem to significantly impact QoL, although in a single report a lower rate of swallowing impairment and diarrhea were found with the transhiatal compared with thoracic esophagectomy [15] .
Unfortunately, only very few data are available on the effect on QoL of the addition of chemoradiotherapy to surgery. One trial compared the QoL of the two approaches in a nonrandomized sample of 99 patients and, while showing comparable levels of long-term QoL, lower degrees of eating problems, diarrhea and appetite loss were found in the chemo-radiotherapy-treated patients [16] . In another series of 41 patients treated with surgery alone or chemo-radiotherapy followed by surgery, the latter group had significantly worse QoL [17] . Finally, in a study surveying 147 patients undergoing surgery alone or chemo-radiotherapy followed by surgery, no differences were detected between the two groups [18] .
Although seldom acknowledged in follow-up studies and not reported in the field of gastrointestinal malignancies, the long-term effects of radiotherapy should be mentioned. Cardiovascular toxicity and mortality are well-known consequences of thoracic irradiation in Hodgkin disease and breast cancer, usually appearing in the second to third decade posttherapy [19] . Similarly, the increased incidence of second malignancies and in particular bone sarcomas should be considered in every patient surviving after a radiotherapy-based treatment [20] .
GASTRIC CANCER
At diagnosis, approximately one-third of patients have localized disease, another third has lymph node involvement and another third has metastatic disease. Surgery is the treatment of choice for patients with loco-regional disease. Chemotherapy with or without radiation can be added to surgery in order to improve survival [21, 22] .
The contribution to long-term QoL of chemotherapy or radiotherapy is not well known, although seems negligible. On the contrary, gastric resection leads to radical changes in the anatomy and physiology of the gastrointestinal tract and can cause long-term symptoms and nutritional complications. After more than 1 year after surgery, 20À30% of the patients still complain of dysphagia, pain, nausea and vomiting, eating restrictions and weight loss [23, 24] . In a retrospective study assessing 126 patients at 5 years after distal subtotal gastrectomy, although there was no statistically significant difference in the global health status compared with the general population, upper gastrointestinal symptoms such as nausea and vomiting, reflux and eating restrictions were more common in survivors [25] . In another series of patients undergoing total gastrectomy, deterioration in QoL lasted more than 5 years, and symptoms such as reflux and eating restrictions were still reported [26] . Fatigue was found to affect approximately half of long-term survivors and was related to poor QoL in a series of 374 patients [27] . The impairment of QoL is strictly dependent on the type of surgery (total or subtotal gastrectomy), and the reconstruction technique (Billroth I, Billroth II or Roux-en-Y), whereas the extent of nodal dissection seems not to be related to long-term outcomes [28, 29] .
KEY POINTS
Long-term consequences of treatment are a frequent occurrence in survivors of gastrointestinal cancer.
Surgery is the most involved treatment in esophageal, gastric and pancreatic cancer, whereas chemotherapy and radiotherapy are important contributors to the impaired QoL in colorectal cancer.
Symptom surveillance and periodic physical examination are the most important suggested practices and should be carried out indefinitely. Laboratory and instrumental examination are necessary in selected patients.
Nutritional issues, physical activity and psychological support are lifestyle interventions that can impact on long-term QoL.
The postgastrectomy syndromes result from the loss of reservoir function, denervation or disruption of the pyloric mechanism. They involve about 25% of all patients following gastric surgery, although only 1-4% develop severe symptoms. In patients undergoing total gastrectomy, a restricted food reservoir is the more serious consequence, compared with partial gastrectomy: the surgical creation of a food reservoir may eliminate the source of restrictive symptoms.
Dumping syndromes, afferent and efferent loop syndromes, Roux-en-Y stasis syndrome and bile reflux are other conditions related to gastrointestinal reconstruction techniques that can lead to a reduction of food intake and occasionally to severe malnutrition [30] . Among these, Roux-en-Y reconstruction results in less dumping syndrome and better QoL than Billroth reconstructions [31] . Although most symptoms worsen in the first months of the postoperative period, recovery is seldom complete at 1 year and some symptoms usually persist longer (pain, reflux, fatigue and nausea) [32] .
Along with feeding issues, three metabolic and nutritional disorders may occur: anemia, bone disease and malabsorption [33] . Anemia is a common finding after gastrectomy and is driven by iron and vitamin B12 deficiency. The first is due to the impairment of iron absorption (reduction of acid and pepsin secretion and, in Billroth II and Rou-en-y reconstructions, lack of duodenal transit) and results in microcytic anemia, the most common finding. Vitamin B12 deficiency is due to the altered secretion of intrinsic factor: it results in macrocytic anemia and can also cause peripheral neuropathy. After total gastrectomy, anemia is almost universal, while it occurs in approximately 15% of patients undergoing partial surgeries [34] . Periodic monitoring of red-cell count, iron metabolism and vitamin B12 blood levels is strongly recommended after gastric surgery. Supplementation should be provided in the case of anemia or iron/vitamin B12 deficit.
Bone disease, namely osteopenia and osteoporosis, is a common consequence of gastrectomy [35] which is due to the impairment of calcium and vitamin D absorption and may become apparent many years after surgery. Clinicians should be aware of this late effect and suggest prevention and treatment of bone loss when appropriate.
Malabsorption is related to the accelerated passage of bolus through the jejunum and to bacterial overgrowth. Although it is quite common in the postoperative period, it usually resolves after weeks or months. Regular weight control, physical examination and, in the case of suspected malabsorption, blood and fecal tests are the suggested practices.
LIVER CANCER
Hepatocellular carcinoma is frequently diagnosed in an advanced stage, and survivorship is an uncommon condition. The overall 10-year survival rate of patients undergoing hepatic resection is less than 10% [36, 37] . In very early stages (tumor less than 2 cm and good liver function), radiofrequency ablation and percutaneous ethanol injection achieve results comparable with surgical resection without any substantial impact on QoL [38] . For patients with more advanced disease, hepatic resection is the treatment of choice. In a small, noncontrolled trial, long-term QoL after surgery was not worse than after radiofrequency ablation and chemoembolization [39] .
The most severe consequence of liver cancer treatment is the worsening of liver function that can occur in the context of chronic liver disease. Adequate selection of surgical candidates is essential for avoiding postoperative complications: patients with good liver function have 5-year survival rates of 55À71%. In these patients, surgery seems to have no significant impact on QoL and the recovery to the preoperative state is complete in 6 months [40,41 & ,42] . Patients with cirrhosis, however, have high rates of morbidity and mortality, in particular due to bleeding and infections [43] . The most effective treatment in appropriately selected patients is liver transplantation [44] . In a recent comprehensive review on patients transplanted for several liver diseases, after 5 years from surgery overall QoL is similar to the general population, although physical function remains worse. Postoperative complications and physical activity after surgery are the two variables involved in long-term QoL [45 && ].
PANCREATIC CANCER
Pancreatic cancer represents one of the major causes of cancer-related death worldwide [46] . Fewer than 10% of patients present with resectable disease, with an overall 5-year survival rate of less than 10% for patients with regional disease [47] . Surgery may result in high postoperative early and late morbidity. Although early complications are mostly self-limited, long-term morbidity (endocrine and exocrine dysfunction) can have a profound impact on QoL. Belyaev et al. [48] observed, in a retrospective analysis of 174 surgical patients, that age and development of pancreatic insufficiency were relevant prognostic factors and affected the postoperative QoL. These results confirmed the findings of other authors demonstrating that newly developed exocrine pancreatic insufficiency impaired QoL in the first 12 months after surgery [49 steatorrhea-related symptoms are the most important finding of exocrine impairment. Patients suffering from exocrine insufficiency should receive enzyme replacement therapy. Undertreatment causes are steatorrhea, weight loss and malnutrition [51] . Recently, Epelboym et al. [52 & ] observed a lack of difference in terms of QoL in patients after total and partial pancreatectomy. In a prospective consecutive series of 136 patients undergoing pancreaticoduodenectomy or distal pancreatectomy, nutritional status, pancreatic endocrine function and QoL returned to preoperative levels in only 46, 53 and 57% of cases, respectively, within 6 months from surgery [53] . The European Study Group for Pancreatic Cancer (ESPAC)-1 study randomized patients between surgery alone, adjuvant chemotherapy and adjuvant chemoradiotherapy. In a subset analysis, QoL was not influenced by postoperative treatment [54] . Similar results were reported in other series [55] . Long-term surveillance through periodic symptom evaluation is thus justified in patients undergoing pancreatic surgery. Appropriate diagnosis and treatment of endocrine or exocrine dysfunctions can restore a normal QoL.
COLORECTAL CANCER
Currently, the combination of earlier diagnosis and improved treatment results in an overall 5-year survival rate of about 65%, which increases up to 70 and 90% for regional and local colorectal cancer, respectively [56] . The main long-term treatment-related consequences are bowel and urinary dysfunction, bone damage, peripheral neuropathy, sexual dysfunction and fertility reduction. Bowel dysfunction represents a major complication of treatments: chronic diarrhea is reported by 13À50% of patients up to 10 years after treatment and is more frequent in rectal cancer [57] . Colonic surgery causes a modification of gut microbiota, a reduction of short-chain fatty acid production and an increase in endotoxemia [58, 59] . Common symptoms associated with anterior resection are evacuatory difficulties, frequent bowel movements and inability to differentiate stool and gas [60] [61] [62] , whereas about 40% of patients who undergo a total mesorectal excision report fecal incontinence; an anastomotic level lower than 6 cm from the anal junction significantly increases the risk of combined fecal and urinary incontinence [63] . Both preoperative and postoperative radiations for rectal cancer amplify the risk of bowel dysfunction [64 & , [65] [66] [67] . Radiotherapy can induce bone damage. A large retrospective study reported a 65% increase in the cumulative incidence of pelvic fractures of rectal cancer survivors after radiation compared with nonirradiated patients [68] .
The addition of oxaliplatin to adjuvant chemotherapy regimens has resulted in a significant survival improvement. However, the accumulation of platinum derivatives within dorsal root ganglia induces an axonopathy of large myelinated fibers resulting in a 12À18% rate of chronic neurotoxicity, with loss of sensation and dysesthesias in distal extremities [69] . Clinical predictive factors of persistent neuropathy associated with oxaliplatin are a body surface more than 2, hypoalbuminemia, hypomagnesemia, anemia, oxaliplatin cumulative dose and a prior acute neuropathy [70,71,72 & ]. Differently from the dihydrophyrimidine dehydrogenase genetic variants, associated with fluoropyrimidine toxicity, no gene polymorphisms showed a sufficient correlation with neurotoxicity for use in clinical practice [73] , although a relationship with the genetic variants of glutathione S-transferase has been reported in several retrospective studies [74, 75] . Ca/Mg infusion [76] , Gosha-jinki-gan, vitamin E and vitamin B16 did not demonstrate a preventive potential, and there are no agents recommended for this aim. Data support a moderate recommendation for the use of duloxetine in the treatment of established neuropathy, whereas gabapentin, and a topical gel treatment containing baclofen, amitriptyline and ketamine may be offered in selected patients [77 && ]. A randomized, placebo-controlled, cross-over trial of 231 patients with chemotherapy-induced neuropathy demonstrated that duloxetine at a dose of 30 mg daily for the first week and 60 mg daily for 4 additional weeks reduces not only pain but also numbness and tingling symptoms [78] .
Although urogenital and fertility dysfunctions are frequent long-term effects of colorectal cancer treatments, these issues are rarely acknowledged. Changes in sexuality include erectile/ejaculatory problems and decreased vaginal lubrification; onethird of rectal cancer patients experience urinary incontinence and difficulties in bladder emptying [79] . Interestingly, nerve-sparing total mesorectal excision has been shown to minimize permanent sexual disorders [80, 81] . On the other hand, abdomino-perineal resection has been associated with lower sexual function at 5 years compared with anterior resection [61, 62] . Preoperative radiotherapy for rectal cancer contributes to dyspareunia inducing vaginal stenosis [82] ; the use of vaginal dilatators has demonstrated benefit in maintaining vaginal patency. Fertility is another important issue: a small series on women aged 50 or younger treated with adjuvant fluorouracil, leucovorin and oxaliplatin chemotherapy showed a 41% rate of amenorrhea during chemotherapy and a 16% rate of persistent amenorrhea 1 year after treatment completion [83] . Several approaches for fertility preservation are under investigation, such as gonadotropin-releasing hormone agonist during chemotherapy, ovarian transposition for the duration of radiotherapy and germ line preservation techniques including oocyte and ovarian tissue cryopreservation [84] . Healthcare providers should facilitate discussions concerning fertility and sexual dysfunction and facilitate patient questions [85] .
In addition to the described events, colorectal cancer patients experience a number of physical and psychosocial symptoms including pain, fatigue, sleep difficulties, fear of cancer recurrence, financial hardship and changes in body image [86 & ]. Negative feelings about body appearance are more frequently described for patients with diverting ostomy, although the QoL of older rectal cancer patients does not seem impaired by a permanent stoma [87] . Physical activity is frequently quoted as a useful intervention aimed at improving QoL [88] . Lifestyle interventions including also dietary recommendations and psychosocial support are recommended practices for patients facing treatment-related hardships.
CONCLUSION
A significant proportion of patients surviving gastrointestinal cancers have a reduced QoL and suffer from some treatment-related toxicity. Surgeries have a major impact, especially in esophageal, gastric and pancreatic cancer. The addition of radiotherapy and/or chemotherapy usually contributes to an overall worsening of treatment-related adverse events. All the providers of survivorship care should be aware of these problems, should be able to offer the best available supportive treatments and provide adequate counseling in the case of irreversible damage. Moreover, adequate and comprehensive information should be given to patients before embarking on treatment.
Finally, it should be emphasized that little information is available about long-term treatmentrelated consequences, and active research should be encouraged. Two major goals should be pursued by research in this field: long-term follow-up data of the studies assessing new treatments should be published so that complete information becomes available to the clinician and the patient and data mining approaches, collecting all the relevant healthrelated events of the treated patients could contribute to the discovery of low-incidence but potentially severe toxicities.
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